| 
| 
Vaccine Adverse Events In Kenya (VAIEK) is a population-based, post-introduction vaccine safety surveillance study of PCV10 in Kenya that will help inform World Health Organization (WHO) vaccine policy.
Synflorix (PCV10) is a 10-valent vaccine against pneumonia presented as a 2-dose vial without a 
preservative. The vaccine was introduced in the routine immunisation schedule in Kenya in February 2011. This is the first time a preservative-free multi-dose vaccine is being used in a developing country. The VAIEK study will provide data on the use of preservative-free vaccines in developing countries such as Kenya.
The study is being conducted at four sites; Kilifi Health and Demographic Surveillance System (Kilifi HDSS), the KEMRI/CDC Research and Public Health Collaboration International Emerging Infections Program (IEIP) population-based disease surveillance sites in Kibera and Rarieda District, and the KEMRI/CDC HDSS Site in Siaya District. The combined annual birth cohort of the 4 sites is approximately 18,500.
The researchers are investigating adverse events following immunisation (AEFI) associated with PCV10. They utilize data from Health and Demographic Surveillance Systems (HDSS). HDSS are population-based and routinely collect records of births, deaths, vaccination and hospitalizations. In addition, the researchers conduct clinic- and household-based surveillance to investigate suspected injection-site abscesses. Shock and all-cause mortality are investigated through hospital-based and demographic surveillance.
The study team sends a report to WHO and other stakeholders every 6 months. Interim study results are described in the May 2012 WHO statement on immunisation standards and show that there was no detectable increase in AEFIs associated with the use of two-dose preservative free PCV10; however, additional data collection is ongoing and conclusions are pending analyses of the entire study results.
The study is a collaboration between the Division of Vaccines and Immunizations (DVI) in Kenya, KEMRI-Wellcome Trust Research Programme and the KEMRI/CDC Research and Public Health, and is funded by GSK Biologicals.
A Common Disease, A Promising Solution Cialis (Tadalafil)
Rotavirus vaccine trial shows dramatic cuts in severe cases of diarrheal illness in Kenya
Rotavirus is the most common cause of severe diarrhea among infants and children worldwide. While RotaTeqTM, a rotavirus vaccine approved by the FDA in 2006, is readily available in the United States, the virus continues to cause an estimated 600,00...
Read more
The 2nd Medical and Veterinary Virus Research in Kenya (MVVR) symposium
Showcasing Virology Research in the Region Viral pathogens exert a heavy disease burden on human and other animal populations worldwide. This applies to Kenya, and hence there is considerable medical and veterinary viral research undertaken with the aim of understanding more about the interactions between viruses and their hosts, in terms...
Read more
Odeny Wins Grant for TB Project
KEMRI/CDC’s Tuberculosis Branch will be engaging in a new and innovative study of mobile technologies to control TB after winning a Sh. 9 million grant from the Grand Challenges Canada.
The proposal’s unique use of mobile phones and incorporation of new business model, that is, in disseminating health messages, are the reasons behind the...
Read more
KEMRI/CDC in Kisumu ASK Show 2012
KEMRI/CDC’s HIV Implementation Science and Services (HISS) Testing and Counseling team, for the first time tested more men than women during the Kisumu Agricultural Society of Kenya (ASK) show. The team tested 287 people during the 2012 Kisumu ASK show which was held between 18th and 22nd July at Mamboleo grounds. “Ever since we starte...
Read more